ADC Therapeutics SA

1.35
0.00 (0.00%)
At close: Apr 02, 2025, 3:59 PM
1.32
-2.22%
Pre-market: Apr 03, 2025, 07:20 AM EDT

ADC Therapeutics SA Statistics

Share Statistics

ADC Therapeutics SA has 99.08M shares outstanding. The number of shares has increased by 2.97% in one year.

Shares Outstanding 99.08M
Shares Change (YoY) 2.97%
Shares Change (QoQ) 2.48%
Owned by Institutions (%) 53.89%
Shares Floating 77.81M
Failed to Deliver (FTD) Shares 770
FTD / Avg. Volume 0.17%

Short Selling Information

The latest short interest is 5.18M, so 5.36% of the outstanding shares have been sold short.

Short Interest 5.18M
Short % of Shares Out 5.36%
Short % of Float 6.68%
Short Ratio (days to cover) 5.96

Valuation Ratios

The PE ratio is -1.22 and the forward PE ratio is -1.15. ADC Therapeutics SA's PEG ratio is 0.03.

PE Ratio -1.22
Forward PE -1.15
PS Ratio 2.79
Forward PS 0.3
PB Ratio -0.95
P/FCF Ratio -1.55
PEG Ratio 0.03
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for ADC Therapeutics SA.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 3.82, with a Debt / Equity ratio of -1.62.

Current Ratio 3.82
Quick Ratio 3.59
Debt / Equity -1.62
Debt / EBITDA -3.2
Debt / FCF -2.63
Interest Coverage -2.6

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $263.42K
Profits Per Employee $-600.17K
Employee Count 263
Asset Turnover 0.22
Inventory Turnover 0.32

Taxes

Income Tax 166K
Effective Tax Rate -0.11%

Stock Price Statistics

The stock price has increased by -69.53% in the last 52 weeks. The beta is 1.52, so ADC Therapeutics SA's price volatility has been higher than the market average.

Beta 1.52
52-Week Price Change -69.53%
50-Day Moving Average 1.65
200-Day Moving Average 2.51
Relative Strength Index (RSI) 33.16
Average Volume (20 Days) 447.72K

Income Statement

In the last 12 months, ADC Therapeutics SA had revenue of 69.28M and earned -157.85M in profits. Earnings per share was -1.62.

Revenue 69.28M
Gross Profit 63.33M
Operating Income -130.65M
Net Income -157.85M
EBITDA -102.65M
EBIT -105.92M
Earnings Per Share (EPS) -1.62
Full Income Statement

Balance Sheet

The company has 250.87M in cash and 328.09M in debt, giving a net cash position of -77.22M.

Cash & Cash Equivalents 250.87M
Total Debt 328.09M
Net Cash -77.22M
Retained Earnings -1.49B
Total Assets 321.98M
Working Capital 226.92M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -123.83M and capital expenditures -867K, giving a free cash flow of -124.7M.

Operating Cash Flow -123.83M
Capital Expenditures -867K
Free Cash Flow -124.7M
FCF Per Share -1.28
Full Cash Flow Statement

Margins

Gross margin is 91.41%, with operating and profit margins of -188.59% and -227.84%.

Gross Margin 91.41%
Operating Margin -188.59%
Pretax Margin -225.37%
Profit Margin -227.84%
EBITDA Margin -148.17%
EBIT Margin -188.59%
FCF Margin -180%

Dividends & Yields

ADCT does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for ADCT is $8, which is 492.6% higher than the current price. The consensus rating is "Buy".

Price Target $8
Price Target Difference 492.6%
Analyst Consensus Buy
Analyst Count 5
Stock Forecasts

Scores

Altman Z-Score -6.37
Piotroski F-Score 2